Clinical Report: Approaches to the Care of Patients with Lower-Risk Myelodysplastic Syndromes

Overview

Lower-risk myelodysplastic syndromes (LR-MDS) primarily affect elderly patients and are characterized by ineffective hematopoiesis leading to cytopenias and risk of progression to acute myeloid leukemia. Advances in molecular diagnostics and classification systems have improved diagnosis and prognostication, enabling more targeted treatment approaches and better monitoring of treatment response.

Background

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders causing dysplasia and cytopenias, with increased risk of progression to acute myeloid leukemia (AML). LR-MDS represents the majority of cases and is associated with anemia and complications that impact quality of life and mortality. Diagnosis relies on integrated clinical, morphological, cytogenetic, and molecular assessments, with recent classification updates incorporating molecular and immunophenotypic data. Emerging therapies targeting specific pathogenic pathways are improving treatment outcomes for LR-MDS patients.

Data Highlights

Diagnosis of MDS involves peripheral blood smear, bone marrow cytology and histology, cytogenetics, mutational analysis, and flow cytometry immunophenotyping. The 2017 WHO classification and newer 5th edition WHO and ICC classifications guide diagnosis and subclassification. Prognostic tools include IPSS, IPSS-R, and IPSS-M. Molecular markers such as SF3B1 mutations define distinct disease entities. Flow cytometry markers and molecular alterations support diagnosis when morphology is inconclusive.

Key Findings

• LR-MDS mainly affects elderly patients with median onset above 70 years and constitutes the majority of MDS diagnoses.
• Diagnosis requires comprehensive assessment including blood counts, bone marrow studies, cytogenetics, mutational analysis, and flow cytometry.
• Recent classification systems (5th WHO edition, ICC) incorporate molecular and immunophenotypic data to refine diagnosis and prognosis.
• Specific mutations such as SF3B1 define distinct subtypes with characteristic clinical courses.
• Distinguishing MDS-related cytopenias from other causes is critical, especially in the presence of clonal hematopoiesis.
• Emerging therapies target pathways like TGF-β signaling and epigenetic modifications, improving treatment options for LR-MDS.

Clinical Implications

Clinicians should utilize integrated diagnostic approaches including molecular and flow cytometry analyses to accurately diagnose and risk-stratify LR-MDS patients. Recognizing distinct molecular subtypes can guide personalized treatment strategies. Regular monitoring of symptoms and treatment responses, including patient-reported outcomes, is essential to optimize care and improve quality of life.

Conclusion

Advances in molecular diagnostics and classification have enhanced the understanding and management of LR-MDS, enabling more precise diagnosis and targeted therapies. Incorporation of structured response assessments into clinical practice promises improved outcomes for these patients.

References

1. MDS European LeukemiaNet and WHO Classification Updates
2. International Working Group for Flow Cytometry in MDS (IMDS Flow)
3. IPSS, IPSS-R, and IPSS-M Prognostic Tools